Biosensors and X-Cell Medical Reach Agreement to Form New Firm Focused on Next Generation of Drug-Eluting Stents.Business Editors/Health/Medical Writers SINGAPORE & NEWPORT BEACH Newport Beach, residential and resort city (1990 pop. 66,643), Orange co., S Calif., on Newport Bay and the Pacific Ocean; inc. 1906. It is a popular seaside resort and yachting center. Manufactures include electrical and medical equipment, computers, boats, and adhesives. , Calif. & NEW YORK--(BUSINESS WIRE)--Sept. 16, 2003--Biosensors International and X-Cell Medical, Inc. jointly announced today that they have entered into an agreement in principle to create a fully integrated drug-eluting stent In cardiology, a drug-eluting stent is a stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents scar-tissue–like growth that, together with clots (thrombus), could otherwise block the stented (DES) company dedicated to the development and commercialization of new DES technologies using novel anti-restenotic drug candidates. The new company will have a full product offering generated from the combined in-house expertise and proven development track records of Biosensors and X-Cell along the entire DES value chain, from drug discovery and development through formulation and delivery systems to stent manufacturing. The agreement combines Biosensors' core competencies in drug and polymer synthesis, proprietary stent designs and catheter delivery systems with X-Cell's integrated anti-restenosis drug discovery programs, novel compounds and leading scientific team. X-Cell currently has multiple drug candidates in various stages of development and is focused on creating the next generation of DES innovations. "This new venture is very exciting because it will help enable the development of novel DESs for patients who, for a variety of reasons, may be resistant to first generation DESs," said Dr. Andrew Marks, Chief Scientific Advisor at X-Cell and Professor of Molecular Cardiology at Columbia University Columbia University, mainly in New York City; founded 1754 as King's College by grant of King George II; first college in New York City, fifth oldest in the United States; one of the eight Ivy League institutions. . "This is a landmark development in the DES landscape," said Dr. Oded Ben-Joseph, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of X-Cell. "We believe that there is an immense market need for next generation anti-restenotic stent-delivered drugs, and we have created a highly differentiated company, which is uniquely positioned to fill this gap. Furthermore, we are extremely fortunate to have Oxford Bioscience Partners as our financial partner in this opportunity. Oxford is a leading life sciences venture capital firm with tremendous expertise and experience in the drug discovery and medical device arenas." Dr. Martin Leon, Medical Director of X-Cell and Chairman of the Cardiovascular Research Foundation in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , added, "There is tremendous value with this integration of expertise in drug development, advanced carrier vehicles, and futuristic stent platforms. While the initial focus would be next-generation anti-restenotic therapies, there are exciting opportunities to expand stent-based drug delivery into other areas, such as plaque stabilization, angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. and myogenesis therapies, and myocardial myocardial /myo·car·di·al/ (-kahr´de-al) pertaining to the muscular tissue of the heart. myocardial pertaining to the muscular tissue of the heart (the myocardium). preservation after acute infarction." Yoh-Chie Lu, President and CEO of Biosensors, commented, "Refinements in stent design, anti-restenotic drugs and stent coating technology promise to broaden the population of patients who will qualify for stent procedures, allowing them to be treated more effectively and earlier in the coronary disease process and extending their horizon of disease-free survival disease-free survival Oncology The time that a person with a disease lives without known recurrence; DFS is major clinical parameter used to evaluate the efficacy of a particular therapy, which is usually measured in 'units' of 1 or 5 yrs. See Cure, Remission. . We are confident that the combined efforts of X-Cell and Biosensors will result in next-generation innovations in this exciting arena of medicine." About X-Cell Medical X-Cell Medical, Inc. is a development stage biotech company committed to the discovery and development of novel therapeutic products for cardiovascular diseases based on its breakthrough discoveries relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc cell migration and proliferation, pioneered by its leading scientific team. X-Cell Medical was founded by a group of leading cardiovascular physicians in conjunction with Accelerated Technologies, a cardiovascular device accelerator. X-Cell is financially backed by the venture capital firm Oxford Bioscience Partners, a leading life sciences venture capital with over $800 million under management and a long history of assisting innovative companies. About Biosensors International Biosensors focuses its research in the fields of new drug discovery, stent design and local drug delivery coating development for interventional cardiology interventional cardiology Cardiology The subspecialty of cardiology dedicated to the diagnosis, medical and mechanical therapy, pre- and post-procedure management of adult patients with acute and chronic forms of cardiovascular disease amenable to catheter-based markets worldwide. Biosensors International is a subsidiary of Sun Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Limited, and seeks to become a leading company specializing in cardiovascular technology. This week the company launched its first in man Stealth 1 trial using Biolimus A-9 anti-restenotic compound. For more information, please visit http://www.biosensors.com.sg. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion